Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on brain & cognitive health. Browse all Brain & Cognitive Health education

Cannabis is often described as non-addictive, but the evidence tells a more nuanced story. A meaningful share of people who use cannabis go on to develop cannabis use disorder — a pattern of use that becomes hard to control despite negative consequences. Who develops it, and who does not, is shaped substantially by genetics.

How common is cannabis addiction?

Public health data suggest that roughly 3 in 10 people who use cannabis develop some degree of cannabis use disorder, with risk rising sharply for those who start in adolescence or use daily. When researchers ask why some users are affected and others are not, twin and family studies point to a large heritable component: estimates for the genetic contribution to cannabis use disorder often fall in the range of 50% to 70%. In other words, genes do not determine whether someone tries cannabis, but they strongly influence who is vulnerable to losing control of it.

The endocannabinoid system and CNR1

Cannabis acts on the body's endocannabinoid system, and the genes governing that system are prime suspects. CNR1 encodes the CB1 receptor, the main target of THC. Common variants in CNR1 have been associated with differences in cannabis dependence and reward sensitivity, plausibly by altering how strongly the receptor responds. Because CB1 signaling shapes reward, appetite, and mood, small inherited differences here can influence how reinforcing cannabis feels.

FAAH, anandamide, and reward

FAAH is the enzyme that breaks down anandamide, one of the body's own cannabinoids. The well-studied variant rs324420 (C385A) reduces FAAH activity, which raises anandamide levels. Research has connected this variant to differences in stress reactivity, reward processing, and how people respond to cannabis — another example of how the endocannabinoid genes tune vulnerability.

AKT1, CHRNA2, and broader risk

Two more named variants illustrate the range of pathways involved. AKT1 (rs2494732) sits in a dopamine-signaling pathway and has been studied for its link to cannabis-associated psychosis risk in some individuals. Large genome-wide studies have also flagged CHRNA2, a nicotinic receptor gene, as associated with cannabis use disorder — a reminder that addiction genetics often cut across substances rather than being drug-specific. Together, CNR1, FAAH, AKT1, and CHRNA2 show that vulnerability is polygenic, not the work of one gene.

What genetic insight offers here

The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across peptide-related biological pathways. It is an educational, pathway-level tool: it offers context about your underlying biology, not a diagnosis, a treatment plan, or a verdict about cannabis use disorder or any addiction. As the PlexusDx principle puts it, the test tells you about your biology — it does not tell you what to put in your body. Genetics is a guide, not a guarantee, and any variant you carry is one input among many.

Understanding that addiction vulnerability is partly inherited can reduce shame and support earlier, more honest conversations — especially for people with a family history. But a genetic profile cannot diagnose a substance use disorder, predict with certainty who will develop one, or treat it. Cannabis use disorder is assessed and managed by qualified professionals, often with behavioral therapy and support systems. Genetics is context for that care, not a substitute.

Frequently Asked Questions

What percentage of cannabis users become addicted?

Public health estimates suggest about 3 in 10 people who use cannabis develop some degree of cannabis use disorder. Risk is higher for those who begin in adolescence or use daily. Genetics strongly influences vulnerability, with twin studies estimating the heritable contribution at roughly 50% to 70%.

Which genes affect cannabis addiction risk?

Several pathways are involved. CNR1 encodes the CB1 receptor THC targets; FAAH (rs324420) shapes anandamide and reward; AKT1 (rs2494732) sits in a dopamine pathway; and CHRNA2 has been flagged in genome-wide studies. Vulnerability is polygenic, reflecting many small-effect variants rather than one gene.

Does a genetic test predict whether I will become addicted?

No. Genetics shifts the odds but does not determine outcomes. Many people with higher-risk variants never develop cannabis use disorder, and many who do carry none of the studied variants. A test offers pathway-level context about vulnerability, not a prediction and not a diagnosis.

What should I do if I am worried about cannabis use?

Talk with a qualified healthcare provider. Cannabis use disorder is treatable, typically through behavioral therapy, support systems, and structured plans. A family history or genetic context can be useful information to share, but assessment and care should always come from a licensed professional.

Curious how inherited factors and reward pathways shape vulnerability? Explore the Precision Peptide Genetic Test for a pathway-level view of your biology, then bring what you learn to a qualified healthcare provider who can put it in clinical context.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use. Consult a qualified healthcare provider before beginning any peptide protocol.

This article is part of the PlexusDx Education Hub. Browse all Brain & Cognitive Health education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.